3+3 Design [Design Issues]

posted by Pharma_88 – China, 2020-01-07 08:09  – Posting: # 21062
Views: 1,125

Hello All,

This is regarding 3+3 design for Phase-I trial. I have searched online and found some articles on design. My Question is that once the group/cohort is completed with 3 patients, whether same patients will be enrolled in next cohort or new patient will be enrolled? Further, in next cohort suppose 1 patient is withdarwn or have some AE then its compulsory to add 3 more patients to inline with multiplication of 3?

Thanks,
Pharma_88

Complete thread:

Activity
 Admin contact
20,471 posts in 4,300 threads, 1,415 registered users;
online 7 (1 registered, 6 guests [including 4 identified bots]).
Forum time (Europe/Vienna): 12:39 CEST

We should not speak so that it is possible
for the audience to understand us,
but so that it is impossible
for them to misunderstand us.    Quintilian

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5